IMPORTANT SAFETY INFORMATION
MenQuadfi should not be administered to anyone who has had a severe allergic reaction to any
component of the vaccine, or after a previous dose of MenQuadfi or any other tetanus toxoid-containing
Appropriate observation and medical treatment should always be readily available in case of an
anaphylactic event following the administration of the vaccine.
Some individuals with altered immunocompetence, including some individuals receiving
immunosuppressant therapy, may have reduced immune responses to MenQuadfi. Persons with certain
complement deficiencies and persons receiving treatment that inhibits terminal complement activation
(eg, eculizumab) are at increased risk for invasive disease caused by N meningitidis,
including invasive disease caused by serogroups A, C, W, and Y, even if they develop antibodies
following vaccination with MenQuadfi.
Syncope can occur following, or even before, vaccination with MenQuadfi. Procedures should be in
place to prevent falling and injury and to manage syncope.
Guillain-Barré syndrome (GBS) has been reported in temporal relationship following administration of
another US-licensed meningococcal quadrivalent polysaccharide conjugate vaccine. The decision to give
MenQuadfi to persons with a history of GBS should take into account the expected benefits and
Immunization with MenQuadfi does not substitute for routine tetanus immunization.
Vaccination with MenQuadfi may not protect all vaccine recipients.
The most common adverse reactions following a primary dose of MenQuadfi in individuals 2 years of age
and older include pain at the injection site; myalgia, headache, and malaise. Other common adverse
reactions in children 2 through 9 years of age include erythema and swelling at the injection site. In
adolescents and adults, rates of solicited adverse reactions following a booster dose were comparable
to those observed following primary vaccination. Other adverse reactions may occur.
Please see the full
to learn more about Sanofi’s
commitment to fighting counterfeit drugs.
- MenQuadfi [Prescribing Information]. Sanofi Pasteur Inc.
- Kroger A, Bahta L, Hunter P. General best practice guidelines for immunization: best practices guidance of the Advisory Committee on Immunization Practices (ACIP). Centers for Disease Control and Prevention. Updated May 4, 2021. Accessed July 13, 2022. https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html
Back to the top